[1] PARASKEVAIDI M, ALLSOP D, KARIM S, et al. Diagnostic biomarkers for Alzheimer’s disease using non-invasive specimens[J].J Clin Med, 2020, 9(6): 1693
[2] ASDI. World Alzheimer Report 2019: Attitudes to Dementia[R/OL].London: Alzheimer’s Disease International, 2019 [2020-12-01].https://www.alzint.org/resource/world-alzheimer-report-2019/
[3] POLIS B, SAMSON AO. Role of the metabolism of branched-chain amino acids in the development of Alzheimer’s disease and other metabolic disorders[J].Neural Regen Res, 2020, 15(8): 1460
[4] CANTER RG, PENNEY J, TSAI LH. The road to restoring neural circuits for the treatment of Alzheimer’s disease[J].Nature, 2016, 539(7628): 187
[5] BADHWAR A, MCFALL GP, SAPKOTA S, et al. A multiomics approach to heterogeneity in Alzheimer’s disease: focused review and roadmap[J].Brain, 2020, 143(5): 1315
[6] NAZ S, VALLEJO M, GARCIA A, et al. Method validation strategies involved in non-targeted metabolomics[J].J Chromatogr A, 2014, 1353: 99
[7] ENCHE ADY CNA, LIM SM, TEH LK, et al. Metabolomic-guided discovery of Alzheimer’s disease biomarkers from body fluid[J].J Neurosci Res, 2017, 95(10): 2005
[8] LI Y, RUAN Q, LI Y, et al. A novel approach to transforming a non-targeted metabolic profiling method to a pseudo-targeted method using the retention time locking gas chromatography/mass spectrometry-selected ions monitoring[J].J Chromatogr A, 2012, 1255: 228
[9] ZHENG F, ZHAO X, ZENG Z, et al. Development of a plasma pseudotargeted metabolomics method based on ultra-high-performance liquid chromatography-mass spectrometry[J].Nat Protoc, 2020, 15(8): 2519
[10] CHARIDEMOU E, ASHMORE T, GRIFFIN JL, et al. The use of stable isotopes in the study of human pathophysiology[J].Int J Biochem Cell Biol, 2017, 93: 102
[11] MARKLEY JL, BR#xDC;SCHWEILER R, EDISON AS, et al. The future of NMR-based metabolomics[J].Curr Opin Biotechnol, 2017, 43: 34
[12] GRAHAM SF, HOLSCHER C, GREEN BD. Metabolic signatures of human Alzheimer’s disease (AD): 1H NMR analysis of the polar metabolome of post-mortem brain tissue[J].Metabolomics, 2014, 10(4): 744
[13] WU J, FU B, LEI H, et al. Gender differences of peripheral plasma and liver metabolic profiling in APP/PS1 transgenic AD mice[J].Neuroscience, 2016, 332: 160
[14] GONZALEZ-DOMINGUEZ R, SAYAGO A, FERNANDEZ-RECAMALES A. Metabolomics in Alzheimer’s disease: the need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology[J].J Chromatogr B, 2017, 1071: 75
[15] GONZALEZ-DOMINGUEZ R, GARCIA-BARRERA T, GOMEZ-ARIZA JL. Metabolite profiling for the identification of altered metabolic pathways in Alzheimer’s disease[J].J Pharm Biomed Anal, 2015, 107: 75
[16] KIMBALL BA, WILSON DA, WESSON DW. Alterations of the volatile metabolome in mouse models of Alzheimer’s disease[J].Sci Rep, 2016, 6: 19495
[17] WISHART DS, FEUNANG YD, MARCU A, et al. HMDB 4.0: the human metabolome database for 2018[J].Nucleic Acids Res, 2018, 46(D1): D608
[18] GOMEZ-ARIZA J, BARBAS C, GARCIA-BARRERA T, et al. Metabolomic-driven elucidation of serum disturbances associated with Alzheimer’s disease and mild cognitive impairment[J].Curr Alzheimer Res, 2016, 13(6): 41
[19] TANG Z, LIU L, LI Y, et al. Urinary metabolomics reveals alterations of aromatic amino acid metabolism of Alzheimer’s disease in the transgenic CRND8 mice[J].Curr Alzheimer Res, 2016, 13(7): 764
[20] HE J, SUN C, LI T, et al. A sensitive and wide coverage ambient mass spectrometry imaging method for functional metabolites based molecular histology[J].Adv Sci(Weinh), 2018, 5(11): 1800250
[21] GONZALEZ DSRE, MANUEL I, GIRALT MT, et al. Imaging mass spectrometry(IMS) of cortical lipids from preclinical to severe stages of Alzheimer’s disease[J].Biochim Biophys Acta Biomembr, 2017, 1859: 1604
[22] ESTEVE C, JONES EA, KELL DB, et al. Mass spectrometry imaging shows major derangements in neurogranin and in purine metabolism in the triple-knockout 3×Tg Alzheimer mouse model[J].Biochim Biophys Acta, 2017, 1865(7): 747
[23] HUYNH RA, MOHAN C. Alzheimer’s disease: biomarkers in the genome, blood, and cerebrospinal fluid[J].Front Neurol, 2017, 8: 102
[24] MUGURUMA Y, TSUTSUI H, NODA T, et al. Widely targeted metabolomics of Alzheimer’s disease postmortem cerebrospinal fluid based on 9-fluorenylmethyl chloroformate derivatized ultra-high performance liquid chromatography tandem mass spectrometry[J].J Chromatogr B, 2018, 1091: 53
[25] TAKAYAMA T, MIZUNO H, TOYO’OKA T, et al. Isotope corrected chiral and achiral nontargeted metabolomics: an approach for high accuracy and precision metabolomics based on derivatization and its application to cerebrospinal fluid of patients with Alzheimer’s disease[J].Anal Chem, 2019, 91(7): 4396
[26] KOAL T, KLAVINS K, SEPPI D, et al. Sphingomyelin SM(d 18∶1/18∶0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-beta 42, tau, and phospho-tau-181 levels[J].J Alzheimers Dis, 2015, 44(4): 1193
[27] VELPEN V, TEAV T, GALLART-AYALA H, et al. Systemic and central nervous system metabolic alterations in Alzheimer’s disease[J].Alzheimers Res Ther, 2019, 11(1): 93
[28] TRUSHINA E, DUTTA T, PERSSON X, et al. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer’s disease using metabolomics[J].PLoS One, 2013, 8(5): e63644
[29] YILMAZ A, UGUR Z, BISGIN H, et al. Targeted metabolic profiling of urine highlights a potential biomarker panel for the diagnosis of Alzheimer’s disease and mild cognitive impairment: a pilot study[J].Metabolites, 2020, 10: 357
[30] YU J, KONG L, ZHANG A, et al. High-throughput metabolomics for discovering potential metabolite biomarkers and metabolic mechanism from the APPswe/PS1dE9 transgenic model of Alzheimer’s disease[J].J Proteome Res, 2017, 16(9): 3219
[31] YUAN BF, ZHU QF, GUO N, et al. Comprehensive profiling of fecal metabolome of mice by integrated chemical isotope labeling-mass spectrometry analysis[J].Anal Chem, 2018, 90(5): 3512
[32] LUAN H, WANG X, CAI Z. Mass spectrometry-based metabolomics: targeting the crosstalk between gut microbiota and brain in neurodegenerative disorders[J].Mass Spectrom Rev, 2019, 38(1): 22
[33] HUO Z, YU L, YANG J, et al. Brain and blood metabolome for Alzheimer’s dementia: findings from a targeted metabolomics analysis[J].Neurobiol Aging, 2020, 86: 123
[34] VARMA VR, OOMMEN AM, VARMA S, et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: a targeted metabolomics study[J].PLoS Med, 2018, 15(1): e1002482
[35] MAHAJAN UV, VARMA VR, GRISWOLD ME, et al. Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: a targeted metabolomic and transcriptomic study[J].PLoS Med, 2020, 17(1): e1003012
[36] DOMINY SS, LYNCH C, ERMINI F, et al. Porphyromonas gingivalis in Alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors[J].Sci Adv, 2019, 5(1): eaau 3333
[37] TAO H, TRAN T, ZHENG J, et al. Metabolomics analyses of saliva detect novel biomarkers of Alzheimer’s disease[J].J Alzheimers Dis, 2018, 65(4): 1
[38] LAU HC, YU JB, LEE HW, et al. Investigation of exhaled breath samples from patients with Alzheimer’s disease using gas chromatography-mass spectrometry and an exhaled breath sensor system[J].Sensors(Basel), 2017, 17(8): 1783
[39] TIELE A, WICAKSONO A, DAULTON E, et al. Breath-based non-invasive diagnosis of Alzheimer’s disease: a pilot study[J].J Breath Res, 2020, 14(2): 026003
[40] WANG M, CHEN L, LIU D, et al. Metabolomics highlights pharmacological bioactivity and biochemical mechanism of traditional Chinese medicine[J].Chem Biol Interact, 2017, 273: 133
[41] XIA H, WU L, CHU M, et al. Effects of breviscapine on amyloid beta 1-42 induced Alzheimer’s disease mice: a HPLC-QTOF-MS based plasma metabonomics study[J].J Chromatogr B, 2017, 1057: 92
[42] WEI M, LIU Z, LIU Y, et al. Urinary and plasmatic metabolomics strategy to explore the holistic mechanism of lignans in S. chinensis in treating Alzheimer’s disease using UPLC-Q-TOF-MS[J].Food Funct, 2019, 10(9): 5656
[43] LIU Y, LIU Z, WEI M, et al. Pharmacodynamic and urinary metabolomics studies on the mechanism of Schisandra polysaccharide in the treatment of Alzheimer’s disease[J].Food Funct, 2019, 10(1): 432
[44] LI J, LIU Y, LI W, et al. Metabolic profiling of the effects of ginsenoside Re in an Alzheimer’s disease mouse model[J].Behav Brain Res, 2018, 337: 160
[45] ZHANG Y, YANG X, WANG S, et al. Ginsenoside Rg3 prevents cognitive impairment by improving mitochondrial dysfunction in the rat model of Alzheimer’s disease[J].J Agric Food Chem, 2019, 67(36): 10048
[46] GONG Y, LIU Y, ZHOU L, et al. A UHPLC-TOF/MS method based metabonomic study of total ginsenosides effects on Alzheimer disease mouse model[J].J Pharm Biomed Anal, 2015, 115: 174
[47] LI N, ZHOU L, LI W, et al. Protective effects of ginsenosides Rg1 and Rb1 on an Alzheimer’s disease mouse model: a metabolomics study[J].J Chromatogr B, 2015, 985: 54
[48] LI N, LIU Y, LI W, et al. A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer’s disease[J].J Ginseng Res, 2016, 40(1): 9
[49] ZHOU H, TAI J, XU H, et al. Xanthoceraside could ameliorate Alzheimer’s disease symptoms of rats by affecting the gut microbiota composition and modulating the endogenous metabolite levels[J].Front Pharmacol, 2019, 10: 1035
[50] ZHANG M, LIU Y, LIU M, et al. UHPLC-QTOF/MS-based metabolomics investigation for the protective mechanism of Danshen in Alzheimer’s disease cell model induced by Aβ1-42[J].Metabolomics, 2019, 15(2): 13
[51] LI H, LEI T, ZHANG J, et al. Longan (Dimocarpus longan Lour.) Aril ameliorates cognitive impairment in AD mice induced by combination of D-gal/AlCl3 and an irregular diet via RAS/MEK/ERK signaling pathway[J].J Ethnopharmacol, 2021, 267: 113612
[52] ZHANG X, JIANG X, WANG X, et al. A metabolomic study based on accurate mass and isotopic fine structures by dual mode combined-FT-ICR-MS to explore the effects of Rhodiola crenulata extract on Alzheimer disease in rats[J].J Pharm Biomed Anal, 2019, 166: 347
[53] LI X, WANG Y, SU M, et al. Brain metabolomics study for the protective effects of Rhodiola crenulata extract on Alzheimer’s disease by HPLC coupled with Fourier transform-ion cyclotron resonance mass spectrometry[J].J Sep Sci, 2020, 43(16): 3216
[54] OSKOUIE AA, YEKTA RF, TAVIRANI MR, et al. Lavandula angustifolia effects on rat models of Alzheimer’s disease through the investigation of serum metabolic features using NMR metabolomics[J].Avicenna J Med Biotechnol, 2018, 10(2): 83
[55] YANG BY, TAN JY, LIU Y, et al. A UPLC-TOF/MS-based metabolomics study of rattan stems of Schisandra chinensis effects on Alzheimer’s disease rats model[J].Biomed Chromatogr, 2017, 32(33): e4037
[56] RONG W, DING K, GUO S, et al. Metabolomics analysis of Xanthoceras sorbifolia husks protection of rats against Alzheimer’s disease using liquid chromatography mass spectrometry[J].J Chromatogr B, 2019, 1126-1127: 121739
[57] SUN Z, LI Q, BI K. Rapid HPLC-ESI-MS/MS analysis of neurotransmitters in the brain tissue of Alzheimer’s disease rats before and after oral administration of Xanthoceras sorbifolia Bunge[J].J Molecules, 2018, 23(12): 3111
[58] WANG XJ, ZHANG AH, KONG L, et al. Rapid discovery of quality-markers from Kaixin San using chinmedomics analysis approach[J].Phytomedicine, 2019, 54: 371
[59] GAO HL, ZHANG AH, YU JB, et al. High-throughput lipidomics characterize key lipid molecules as potential therapeutic targets of Kaixinsan protects against Alzheimer’s disease in APP/PS1 transgenic mice[J].J Chromatogr B, 2018, 1092: 286
[60] CHU H, ZHANG A, HAN Y, et al. Metabolomics approach to explore the effects of Kai-Xin-San on Alzheimer’s disease using UPLC/ESI-Q-TOF mass spectrometry[J].J Chromatogr B, 2016, 1015-1016: 50
[61] HE Y, WANG Y, LIU S, et al. A metabolomic study of the urine of rats with Alzheimer’s disease and the efficacy of Ding-Zhi-Xiao-Wan on the afflicted rats[J].J Sep Sci, 2020, 43(8): 1458
[62] ZHANG AH, YU JB, SUN H, et al. Identifying quality-markers from Shengmai San protects against transgenic mouse model of Alzheimer’s disease using chinmedomics approach[J].Phytomedicine, 2018, 45: 84
[63] LU S, HAN Y, CHU H, et al. Characterizing serum metabolic alterations of Alzheimer’s disease and intervention of Shengmai-San by ultra-performance liquid chromatography/electrospray ionization quadruple time-of-flight mass spectrometry[J].Food Funct, 2017, 8(4): 1660
[64] SUN LM, ZHU BJ, CAO HT, et al. Explore the effects of Huang-Lian-Jie-Du-Tang on Alzheimer’s disease by UPLC-QTOF/MS-based plasma metabolomics study[J].J Pharm Biomed Anal, 2018, 151: 75
[65] ZHANG Z, YI P, YANG J, et al. Integrated network pharmacology analysis and serum metabolomics to reveal the cognitive improvement effect of Bushen Tiansui formula on Alzheimer’s disease[J].J Ethnopharmacol, 2020, 249: 112371
[66] YE J, YAO JP, WANG X, et al. Neuroprotective effects of ginsenosides on neural progenitor cells against oxidative injury[J].Mol Med Rep, 2016, 13(4): 3083
[67] YAN T, SHANG L, WANG M, et al. Lignans from Schisandra chinensis ameliorate cognition deficits and attenuate brain oxidative damage induced by D-galactose in rats[J].Metab Brain Dis, 2016, 31(3): 653
[68] YAN T, XU M, WAN S, et al. Schisandra chinensis produces the antidepressant-like effects in repeated corticosterone-induced mice via the BDNF/TrkB/CREB signaling pathway[J].Psychiatry Res, 2016, 243: 135
[69] LI N, WANG Y, LI X, et al. Bioactive phenols as potential neuroinflammation inhibitors from the leaves of Xanthoceras sorbifolia Bunge[J].Bioorg Med Chem Lett, 2016, 26(20): 5018
[70] LI W, LU Q, LI X, et al. Anti-Alzheimer’s disease activity of secondary metabolites from Xanthoceras sorbifolia Bunge[J].Food Funct, 2020, 11(3): 2067
[71] DURAIRAJAN SS, HUANG YY, YUEN PY, et al. Effects of Huanglian-Jie-Du-Tang and its modified formula on the modulation of amyloid-beta precursor protein processing in Alzheimer’s disease models[J].PLoS One, 2014, 9(3): e92954
